BR112023000728A2 - Anticorpos contra o muc1-c/domínio extracelular (muc1-c/ecd) - Google Patents
Anticorpos contra o muc1-c/domínio extracelular (muc1-c/ecd)Info
- Publication number
- BR112023000728A2 BR112023000728A2 BR112023000728A BR112023000728A BR112023000728A2 BR 112023000728 A2 BR112023000728 A2 BR 112023000728A2 BR 112023000728 A BR112023000728 A BR 112023000728A BR 112023000728 A BR112023000728 A BR 112023000728A BR 112023000728 A2 BR112023000728 A2 BR 112023000728A2
- Authority
- BR
- Brazil
- Prior art keywords
- muc1
- ecd
- extracellular domain
- antibodies against
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063052599P | 2020-07-16 | 2020-07-16 | |
| PCT/US2021/070881 WO2022016190A1 (en) | 2020-07-16 | 2021-07-15 | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023000728A2 true BR112023000728A2 (pt) | 2023-03-21 |
Family
ID=79554266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023000728A BR112023000728A2 (pt) | 2020-07-16 | 2021-07-15 | Anticorpos contra o muc1-c/domínio extracelular (muc1-c/ecd) |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230265208A1 (https=) |
| EP (1) | EP4182354A4 (https=) |
| JP (1) | JP2023534959A (https=) |
| KR (1) | KR20230116767A (https=) |
| CN (1) | CN117693530A (https=) |
| AU (1) | AU2021310499A1 (https=) |
| BR (1) | BR112023000728A2 (https=) |
| CA (1) | CA3186181A1 (https=) |
| IL (1) | IL299903A (https=) |
| MX (1) | MX2023000784A (https=) |
| WO (1) | WO2022016190A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4676975A1 (en) * | 2023-03-03 | 2026-01-14 | Beone Medicines I GmbH | Muc1 and cd16a antibodies and methods of use |
| AR132043A1 (es) * | 2023-03-03 | 2025-05-21 | Beigene Switzerland Gmbh | Anticuerpos muc1 y métodos de uso |
| WO2025217515A2 (en) | 2024-04-12 | 2025-10-16 | Dana-Farber Cancer Institute, Inc. | Identification of muc1-c as a target for the treatment of squamous cell carcinomas |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005259221B2 (en) * | 2004-07-01 | 2011-02-10 | Innate Pharma | Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use |
| EP3130607B1 (en) * | 2008-10-06 | 2024-04-17 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| WO2015116753A1 (en) * | 2014-01-29 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) |
| US10617773B2 (en) * | 2016-08-05 | 2020-04-14 | Dana-Farber Cancer Institute, Inc. | Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD) |
-
2021
- 2021-07-15 IL IL299903A patent/IL299903A/en unknown
- 2021-07-15 AU AU2021310499A patent/AU2021310499A1/en active Pending
- 2021-07-15 US US18/005,562 patent/US20230265208A1/en active Pending
- 2021-07-15 WO PCT/US2021/070881 patent/WO2022016190A1/en not_active Ceased
- 2021-07-15 CA CA3186181A patent/CA3186181A1/en active Pending
- 2021-07-15 EP EP21842547.8A patent/EP4182354A4/en active Pending
- 2021-07-15 KR KR1020237005383A patent/KR20230116767A/ko active Pending
- 2021-07-15 MX MX2023000784A patent/MX2023000784A/es unknown
- 2021-07-15 CN CN202180063154.3A patent/CN117693530A/zh active Pending
- 2021-07-15 JP JP2023502897A patent/JP2023534959A/ja active Pending
- 2021-07-15 BR BR112023000728A patent/BR112023000728A2/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022016190A1 (en) | 2022-01-20 |
| IL299903A (en) | 2023-03-01 |
| EP4182354A1 (en) | 2023-05-24 |
| EP4182354A4 (en) | 2024-12-25 |
| CN117693530A (zh) | 2024-03-12 |
| AU2021310499A1 (en) | 2023-03-09 |
| JP2023534959A (ja) | 2023-08-15 |
| MX2023000784A (es) | 2023-04-18 |
| KR20230116767A (ko) | 2023-08-04 |
| US20230265208A1 (en) | 2023-08-24 |
| CA3186181A1 (en) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023000728A2 (pt) | Anticorpos contra o muc1-c/domínio extracelular (muc1-c/ecd) | |
| PH12019502282A1 (en) | Bispecific antibodies specifically binding to pd1 and lag3 | |
| MX2021015495A (es) | Composiciones y métodos para tratar cáncer. | |
| MX380864B (es) | Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd). | |
| CL2024002250A1 (es) | Uso de anticuerpo anti-vd1 para tratar cáncer, una enfermedad infecciosa o una enfermedad inflamatoria. | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| MX2022003517A (es) | Anticuerpos anti-pd l1 y conjugados de anticuerpo-farmaco. | |
| DOP2019000253A (es) | Anticuerpos anti-ilt4 y fragmentos de unión a antígeno | |
| MX2022008214A (es) | Nuevas moleculas de union al antigeno que contienen el trimero de 4-1bbl. | |
| BR112019000071A2 (pt) | conjugados adjuvantes de anticorpo | |
| CO2018014413A2 (es) | Anticuerpos anti-c5 y usos de los mismos | |
| BR112019001589A2 (pt) | anticorpos anti-tim-3 | |
| BR112019009617A2 (pt) | anticorpos anti-tim-3 para combinação com anticorpos anti-pd-1 | |
| UY37123A (es) | Anticuerpos y fragmentos anti-vista, usos de los mismos, y metodos para identificar los mismos | |
| BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
| CR20150498A (es) | Anticuerpos de anti-cd134 (ox40) humanizados y usos de los mismos | |
| JOP20220161A1 (ar) | جسم مضاد لـ lilrb1 واستخداماته | |
| CO2022014726A2 (es) | Anticuerpos anti-sea de muc1 | |
| CL2022002571A1 (es) | Agentes de fijación a tie2 y métodos de uso. | |
| CL2023003695A1 (es) | Anticuerpos anti-pcrv que se unen a pcrv, composiciones que comprenden anticuerpos anti-pcrv, métodos de uso | |
| MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
| MX2020007401A (es) | Novedosa combinacion y uso de anticuerpos. | |
| BR112022006620A2 (pt) | Anticorpos contra o receptor de poliovírus (pvr) e seus usos | |
| WO2019182867A8 (en) | Dual specificity antibodies to human pd-l1 and pd-l2 and methods of use therefor | |
| BR112022004831A2 (pt) | Anticorpos que se ligam a vista em ph ácido |